Clinical Trial Update: Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the duration of PD-1/PD-L1 inhibitor therapy in advanced solid tumors; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Colorectal Cancer
• Gastric Cancer
• Head and Neck Squamous Cell Carcinoma
• Hepatocellular Carcinoma
• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• PD-1/PD-L1 inhibitor

Snippet

Sponsor: Dan Zandberg | Conditions: Advanced Solid Tumors, NSCLC | Phase 3 | Status: COMPLETED